Today is the last day to submit a proposal to our Project BioShield #RFP. We’re seeking to support procurement of an approved autograft sparing device to treat burn injuries. Submit by 2:00 PM ET on 7/7. Details and more info:

Help us address long-term burn care challenges and bolster national preparedness. We’re seeking proposals under Project BioShield to support procurement of an approved autograft sparing device to treat burn injuries. Apply to our #RFP by July 7, 2025:

The 1st patient in the JUST BREATHE phase 2 platform clinical trial investigating novel host-directed therapeutic candidates for acute respiratory distress syndrome has been enrolled! We’re working with @PPD to explore treatments that could save lives:

Four BARDA-supported #MedicalCountermeasures have recently received @US_FDA approval, licensure, or clearance. Learn more about these products and how BARDA helps enable their accessibility and availability during health security emergencies:

RT @ASPRgov: This #MLKDay, honor Dr. King's legacy by serving your community. In the latest edition of the ASPR Blog, @MRC_ASPR Deputy Dire….

Tomorrow is the last day to submit your abstract to our Influenza Vaccine Innovation program! We’re seeking to develop novel influenza #vaccines that can provide broader and longer-lasting protection against pandemic #flu Submit by 12 pm ET on 1/20:

We are partnering with @globalsyseng to enhance and modernize CHEMM, our digital resource designed for emergency responders & healthcare providers to access comprehensive information & guidance to aid in preparedness & response for chemical incidents:

Have you heard? We’re on the Bluesky bandwagon! Give us a follow at:

Through @RRPV_Consortium, BARDA expands its partnership w/ mRNA vaccine developer @moderna_tx to expand a rapid pandemic #influenza response capability. This effort aims to make safe & effective #vaccines available more quickly during influenza pandemics.

To help sustain a response-ready posture, we support & maintain a portfolio that helps provide long-term access to #MedicalCountermeasures. This approach bolsters national security & enhances preparedness:

We never stop working to protect the American people. Let’s take a brief look back at our work in 2024 to bolster preparedness for a range of potential health security threats. Learn more:

@DCRINews DCRI will apply its #decentralizedclinicaltrials (DCTs) expertise to advance DCT tools, making #clinicalresearch on medical countermeasures more inclusive and patient centered. Read more about D-COHRe:

We’re excited to announce our newest partner under BARDA’s Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program: @DCRINews!

Through the @RRPV_Consortium, BARDA is partnering with @ShionogiUS to advance a long-acting therapeutic aimed at preventing #COVID19 for people who are immune compromised. Learn more:

We’ve reopened our DRIVe & CBRN ReBooT EZ-BAA area of interest to support the development of repurposed & repositioned direct-acting or host-directed therapeutics to address filovirus (Ebola, Marburg, & Sudan virus) infections. Submission deadline is 4/30:

There's still time to submit your abstract to DRIVe & CBRN’s ReDIRECT program! We seek to support the development of repurposed therapeutics to treat injuries caused by chemical threats. Submissions close March 31:

We are thrilled to announce the Concept Stage winners of the #PatchForwardPrize! Learn more about the winners and how the Patch Forward Prize is advancing microneedle patch-based RNA vaccines: #ProjectNextGen

There's still time to submit your abstract to our Influenza Vaccine Innovation program! We’re seeking to develop novel influenza #vaccines that can provide broader and longer-lasting protection against pandemic #flu. Submit by January 20, 2025:

Decentralized clinical trials (DCTs) offer more convenient access for participants, which can speed enrollment, increase opportunities for data collection, and yield more representative results. Learn more:

RT @ASPRgov: A new peer-reviewed study in @TheLancet reveals that COVID-19 diagnostic test manufacturing, production, & distribution effort….